Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2017 May 1.
Published in final edited form as: JAMA Intern Med. 2016 Nov 1;176(11):1714–1716. doi: 10.1001/jamainternmed.2016.5046

Inclusion of Hypoglycemia in Clinical Practice Guidelines and Performance Measures in the Care of Patients With Diabetes

Rene Rodriguez-Gutierrez, Naykky Singh Ospina, Rozalina G McCoy, Kasia J Lipska, Nilay D Shah, Victor M Montori; for the Hypoglycemia as a Quality Measure in Diabetes Study Group
PMCID: PMC5338305  NIHMSID: NIHMS850462  PMID: 27653613

Health care organizations use publicly reported performance measures for quality measurement and improvement and pay-for-performance initiatives.1 These measures should ideally promote high-quality care that is evidence based and congruent with clinical practice guidelines. However, they should also reward patient-centered care that yields optimal outcomes with the lowest risk of harm.2 For patients with both type 1 and type 2 diabetes, high-quality care should therefore minimize the risk of hypoglycemia.2 The degree to which existing performance measures are aligned with guidelines, particularly in regard to hypoglycemia avoidance, is uncertain. We therefore conducted an environmental scan to assess the inclusion and prioritization of hypoglycemia in contemporary clinical guidelines and performance measures for patients with diabetes.

Methods

A 2-step environmental scan process was used to identify contemporary guidelines and performance measures from January 1, 2010, to March 15, 2016. The terms diabetes, guidelines, and standards of care were used to identify clinical guidelines about diabetes. This search was strengthened with a search in the National Guideline Clearinghouse. Diabetes, quality, performance measures, quality-metric, and quality measure were used to identify quality measures initiatives. A comprehensive search was also performed in the National Quality Measures Clearinghouse. Chance-adjusted agreement for selection of guideline and performance measures initiatives between reviewers working independently was excellent (κ = 0.83 and κ = 0.91, respectively). Disagreements were resolved by consensus. Eligible guidelines and performance measures were the latest published full-text versions of systematically developed statements produced under the auspices of medical specialty or professional associations or public or private organizations at a federal, state, or local level. Neither institutional review board approval nor patient consent was required.

Results

We identified 18 diabetes practice guidelines and 23 performance measures initiatives. All practice guidelines advocated for hypoglycemia ascertainment and treatment, although supported by evidence at varying risk of bias (Table 1). However, only 2 organizations, the National Institute of Health Excellence and the National Information Diabetes Service in the United Kingdom, had issued corresponding performance measures that addressed hypoglycemia. These measures addressed severe not mild hypoglycemia (Table 2), defined as hypoglycemic events that required assistance of others for treatment. The remaining 21 performance measures did not address hypoglycemia ascertainment, treatment, or prevention. In contrast, 80% to 90% of diabetes care performance measure initiatives included multiple surrogate outcome or process measures, such as hemoglobin A1c measurement and target level; low-density lipoprotein cholesterol target level; blood pressure control; nephropathy, retinopathy, and neuropathy screening; smoking cessation; and aspirin use for patients with atherosclerotic cardiovascular disease.

Table 1.

Clinical Practice Guidelines for Patients With Diabetes

Guideline Author, Year Country
American Diabetes Association, 2016 United States
American Association of Clinical Endocrinologist and
American College of Endocrinology, 2016
United States
National Institute for Health Excellence, 2015 United Kingdom
American Diabetes Association and the European
Association for the Study of Diabetes, 2015
United States and
Europe
Royal Australian College of General Practitioners and
Diabetes Australia, 2014–2015
Australia
Health Technology Assessment Section Medical
Development Division Ministry of Health Malaysia,
2015
Malaysia
Joslin Diabetes Center Guidelines, 2014 United States
Institute for Clinical Systems Improvement Guidelines,
2014
United States
Canadian Diabetes Association, 2013 Canada
Association Latinoamericana de Diabetes, 2013 Multiples countries
(approximately 30)
Health Improvement Scotland, SIGN Scotland
The Japan Diabetes Society, 2013 Japan
International Diabetes Federation, 2012 160 Countries
Society for Endocrinology, Metabolism and Diabetes
of South Africa, 2012
South Africa
Society of Endocrinology, Metabolism and Diabetes
in South Africa, 2012
South Africa
University of Michigan Health System, 2012 United States
Kidney Disease Outcomes Quality Initiative United States
Veterans Affairs Guideline and Department of Defense,
2010
United States
a

All of the guidelines include a recommendation on hypoglycemia. Most guidelines state that a less stringent glucose goal should be considered (hemoglobin A1c, 7%–8% [to convert to proportion of hemoglobin, multiply by 0.01]) in patients with a history of severe hypoglycemia, limited life expectancy, advanced renal disease or macrovascular complications, extensive comorbid conditions, or long-standing diabetes mellitus in which the hemoglobin A1c goal has been difficult to attain despite intensive efforts as long as the patient remains free of polydipsia, polyuria, polyphagia, and other hyperglycemia-associated symptoms.

Table 2.

Performance Measures Initiatives for Patients With Diabetes

Institution, Year Country Hypoglycemia
as Quality
Measure
National Institute for Health and
Care Excellence, 2011
United Kingdom Yes
National Diabetes Information
Service, 2011
United Kingdom Yes
Health Resources and Services
Administration, 2012
United States No
International Diabetes Federation,
2012
170 Countries and
230 national
diabetes associations
No
Australian Institute of Health
and Welfare, 2013
Australia No
Centers for Medicare & Medicaid
Services electronic health records,
2014
United States No
National Quality Forum, 2014 United States No
Institute of Clinical Systems
Improvement, 2014
United States No
American Board of Family Medicine,
2014
United States No
Ministerio de Salud Resolucion No.
1156/2014,2014
Argentina No
National Committee for Quality
Assurance, 2015
United States No
Pharmacy Quality Alliance, 2015 United States No
Minnesota Health Scores, the D5
for Diabetes, 2015
United States No
Diabetes Collaborative Registry, 2015 United States No
BlueCross BlueShield, 2015 United States No
Wisconsin Collaborative Health Care,
2015
United States No
Accountable care organizations,
2015
United States No
Physician Quality Reporting System,
2015
United States No
Sharp Rees-Stealy Medical Group
D-9, 2015
United States No
Health Technology Assessment
Section Medical Development
Division Ministry of Health Malaysia,
2015
Malaysia No
Ministry of Health Singapore, 2015 Singapore No
University of Michigan Health
System, 2015
United States No
The Healthcare Effectiveness
Data and Information Set, 2016
United States No

Discussion

The goals of diabetes care are to increase the patients’ longevity, decrease the risk of acute and chronic complications, and increase the health-related quality of life. Considering the substantial morbidity, associated mortality, and decreased quality of life caused by hypoglycemia,36 its prevention is an integral part of patient-centered diabetes care along with hemoglobin A1c control, as reinforced by clinical practice guidelines. However, it remains surprising that less than 10% of the initiatives included a corresponding hypoglycemia performance measure. Efforts are under way to develop reliable, measurable, actionable, and meaningful hypoglycemia measures. These measures may include documentation of hypoglycemic events at each visit, hypoglycemia awareness and management education programs, prescription and patient use of diabetes medical alerts, or prescriptions of glucagon and/or glucose tablets. Engagement of patients to identify and address precipitating causes of hypoglycemia, including treatment regimen change, can also be recorded. When carefully constructed and implemented, a hypoglycemia-focused performance measure would serve as a counterbalance for the current measures. It would be a paradigm shift in the care for patients with diabetes because it would facilitate a holistic approach that prioritizes not only efficacy but also safety and patient-centeredness of diabetes care.

Footnotes

Author Contributions: Drs Montori and Rodriguez-Gutierrez had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Rodriguez-Gutierrez, Singh Ospina, Lipska, Montori.

Acquisition, analysis, or interpretation of data: Rodriguez-Gutierrez, Singh Ospina, McCoy, Montori.

Drafting of the manuscript: Rodriguez-Gutierrez.

Critical revision of the manuscript for important intellectual content: Rodriguez-Gutierrez, Singh Ospina, McCoy, Lipska, Montori.

Statistical analysis: Singh Ospina.

Obtaining funding: Rodriguez-Gutierrez.

Administrative, technical, or material support: Rodriguez-Gutierrez, Singh Ospina, Montori.

Study supervision: Rodriguez-Gutierrez.

Conflict of Interest Disclosures: Dr Lipska reported receiving support from the Centers for Medicare & Medicaid Services to develop and maintain publicly reported quality measures. No other disclosures were reported.

Group Members: The members of the Hypoglycemia as a Quality Measure in Diabetes Study Group are as follows: Yogish C. Kudva, MBBS, Kasia J. Lipska, MD, Rozalina G. McCoy, MD, MS, Victor M. Montori, MD, MSc, Rene Rodriguez-Gutierrez, MD, MSc, Nilay D. Shah, PhD, Naykky Singh Ospina, MD, MSc, and Henry H. Ting, MD, MBA.

Additional Contributions: Patricia Erwin, MLS, expert librarian from the Mayo Clinic, provided valuable assistance with the search strategy. She was not financially compensated for this service.

References

  • 1.National Quality Forum. [Accessed March 15, 2016];Endocrine measures. http://www.qualityforum.org/projects/endocrine/?section=CandidateConsensusStandardsReview2013-12-092014-04-02. Published 2014.
  • 2.Rodriguez-Gutierrez R, Lipska KJ, McCoy RG, Ospina NS, Ting HH, Montori VM. Hypoglycemia as a Quality Measure in Diabetes Study Group. Hypoglycemia as an indicator of good diabetes care. BMJ. 2016;352:i1084. doi: 10.1136/bmj.i1084. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.McCoy RG, Van Houten HK, Ziegenfuss JY, Shah ND, Wermers RA, Smith SA. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care. 2012;35(9):1897–1901. doi: 10.2337/dc11-2054. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Goto A, Arah OA, Goto M, Terauchi Y, Noda M. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ. 2013;347:f4533. doi: 10.1136/bmj.f4533. [DOI] [PubMed] [Google Scholar]
  • 5.Zoungas S, Patel A, Chalmers J, et al. ADVANCE Collaborative Group. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363(15):1410–1418. doi: 10.1056/NEJMoa1003795. [DOI] [PubMed] [Google Scholar]
  • 6.McCoy RG, Van Houten HK, Ziegenfuss JY, Shah ND, Wermers RA, Smith SA. Self-report of hypoglycemia and health-related quality of life in patients with type 1 and type 2 diabetes. Endocr Pract. 2013;19(5):792–799. doi: 10.4158/EP12382.OR. [DOI] [PubMed] [Google Scholar]

RESOURCES